Cas:102488-47-1 1H,1H,2H,2H-PERFLUOROOCTYLDIMETHYLCHLOROSILANE manufacturer & supplier

Chemical Name:1H,1H,2H,2H-PERFLUOROOCTYLDIMETHYLCHLOROSILANE

CAS.NO:102488-47-1

Synonyms:Silane, chlorodimethyl(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)-;chloro-dimethyl-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane;Chloro(dimethyl)(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane;MFCD00042359

Molecular Formula:C₁₀H₁₀ClF₁₃Si

Molecular Weight:440.704

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:213.0±40.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.331

PSA:

Exact Mass:440.003265

LogP:7.54

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:2986

Packing Group:III

Contact us for information like Silane, chlorodimethyl(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)- chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,MFCD00042359 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00042359 Use and application,chloro-dimethyl-(3,3,4,4,5,5,6,6,7,7,8,8,8-tridecafluorooctyl)silane technical grade,usp/ep/jp grade.

Related News: Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. 1H,1H,2H,2H-PERFLUOROOCTYLDIMETHYLCHLOROSILANE manufacturer The second is known as the excipient, which is the inactive substance that serves as the vehicle for the API itself. 1H,1H,2H,2H-PERFLUOROOCTYLDIMETHYLCHLOROSILANE supplier Darzalex does have another regimen approved for the same myeloma population. Darzalex combined with Takeda’s Velcade, melphalan and prednisone (VMP) reduced the risk of death by 40% in the phase 3 ALCYONE trial. But disease progression had already occurred in half of patients on the Darzalex-VMP combo after about three years of follow-up, a much shorter period than the five-year mark the Darzalex-Rd regimen is approaching. 1H,1H,2H,2H-PERFLUOROOCTYLDIMETHYLCHLOROSILANE vendor Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend. 1H,1H,2H,2H-PERFLUOROOCTYLDIMETHYLCHLOROSILANE factory Bristol-Myers Squibb (BMS) recently acquired Celgene, for example, which had the highest proportional R&D spend.